| Complement and coagulation cascades |
1.94 |
5.25e-2 |
76/85 (89.41%) |
SERPINA1;A2M;PROS1;...
|
| ECM-receptor interaction |
1.76 |
1.26e-1 |
80/88 (90.91%) |
COL6A2;COL1A1;COL4A5;...
|
| Amoebiasis |
1.71 |
1.82e-1 |
99/102 (97.06%) |
GNA11;PIK3R1;COL1A1;...
|
| DNA replication |
1.70 |
1.47e-1 |
34/36 (94.44%) |
PCNA;FEN1;MCM5;...
|
| Chagas disease |
1.70 |
1.20e-1 |
93/102 (91.18%) |
GNA11;C3;CCL2;...
|
| Other types of O-glycan biosynthesis |
1.68 |
1.22e-1 |
29/47 (61.7%) |
ST6GAL1;GALNT2;RFNG;...
|
| AGE-RAGE signaling pathway in diabetic complications |
1.67 |
1.17e-1 |
97/100 (97%) |
ICAM1;EGR1;CCL2;...
|
| Systemic lupus erythematosus |
1.67 |
1.05e-1 |
45/135 (33.33%) |
C3;ELANE;C7;...
|
| Type II diabetes mellitus |
1.67 |
9.68e-2 |
42/46 (91.3%) |
PIK3R1;PKM;INSR;...
|
| Wnt signaling pathway |
1.58 |
2.03e-1 |
124/166 (74.7%) |
SERPINF1;SFRP1;TBL1X;...
|
| Vitamin digestion and absorption |
1.57 |
2.00e-1 |
17/24 (70.83%) |
SLC19A2;SLC5A6;APOB;...
|
| Staphylococcus aureus infection |
1.56 |
2.05e-1 |
72/95 (75.79%) |
ICAM1;KRT19;CFB;...
|
| Coronavirus disease |
1.55 |
2.16e-1 |
215/232 (92.67%) |
RPS4Y1;CFB;C3;...
|
| Caffeine metabolism |
1.54 |
2.08e-1 |
5/6 (83.33%) |
NAT1;CYP2A6;CYP1A2
|
| Estrogen signaling pathway |
1.53 |
2.06e-1 |
119/137 (86.86%) |
KRT19;KRT14;PIK3R1;...
|
| Endocrine and other factor-regulated calcium reabsorpti... |
1.53 |
1.94e-1 |
49/53 (92.45%) |
ESR1;PLCB1;AP2M1;...
|
| Base excision repair |
1.53 |
1.88e-1 |
29/33 (87.88%) |
PCNA;FEN1;POLE3;...
|
| Pertussis |
1.45 |
3.16e-1 |
64/76 (84.21%) |
C3;ITGAM;TNF;...
|
| GnRH signaling pathway |
1.44 |
3.32e-1 |
80/93 (86.02%) |
GNA11;EGR1;PLCB1;...
|
| Prostate cancer |
1.43 |
3.40e-1 |
93/97 (95.88%) |
PIK3R1;PLAT;FGFR2;...
|
| Long-term depression |
1.41 |
3.76e-1 |
55/60 (91.67%) |
GRIA2;GNA11;PLCB1;...
|
| Cortisol synthesis and secretion |
1.40 |
3.64e-1 |
58/65 (89.23%) |
GNA11;PLCB1;ADCY1;...
|
| Focal adhesion |
1.39 |
3.86e-1 |
180/201 (89.55%) |
COL6A2;PIK3R1;COL1A1;...
|
| ErbB signaling pathway |
1.38 |
3.99e-1 |
79/85 (92.94%) |
CBLB;NCK1;PIK3R1;...
|
| Vasopressin-regulated water reabsorption |
1.37 |
4.05e-1 |
40/44 (90.91%) |
AQP3;DCTN4;DYNC1H1;...
|
| Growth hormone synthesis, secretion and action |
1.35 |
4.43e-1 |
108/119 (90.76%) |
GNA11;PIK3R1;PLCB1;...
|
| Phosphatidylinositol signaling system |
1.35 |
4.36e-1 |
82/97 (84.54%) |
PIK3R1;INPP5A;PLCB1;...
|
| Nicotine addiction |
1.34 |
4.33e-1 |
32/40 (80%) |
GRIA2;GABRP;GABRE
|
| Protein digestion and absorption |
1.34 |
4.37e-1 |
78/103 (75.73%) |
MME;COL6A2;COL1A1;...
|
| African trypanosomiasis |
1.33 |
4.33e-1 |
32/37 (86.49%) |
ICAM1;PLCB1;IDO1;...
|
| Tryptophan metabolism |
-1.29 |
3.81e-1 |
35/42 (83.33%) |
TDO2;ALDH8A1;MAOA;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
-1.30 |
3.88e-1 |
62/70 (88.57%) |
ATP6V0A2;ATP6V1E1;RAC1;...
|
| Terpenoid backbone biosynthesis |
-1.31 |
3.88e-1 |
18/22 (81.82%) |
FNTA;GGPS1;PDSS1;...
|
| Fatty acid degradation |
-1.32 |
3.78e-1 |
40/43 (93.02%) |
ADH5;ACAA2;ACSBG1;...
|
| Histidine metabolism |
-1.32 |
3.76e-1 |
16/22 (72.73%) |
HAL;MAOA;ALDH3B1;...
|
| Glycerolipid metabolism |
-1.33 |
3.58e-1 |
44/61 (72.13%) |
AKR1B10;DGKB;ALDH1B1;...
|
| Collecting duct acid secretion |
-1.34 |
3.67e-1 |
22/27 (81.48%) |
SLC4A1;ATP4B;ATP6V0A2;...
|
| Dilated cardiomyopathy |
-1.35 |
3.56e-1 |
86/96 (89.58%) |
TGFB3;CACNB1;ITGB5;...
|
| Proximal tubule bicarbonate reclamation |
-1.35 |
3.62e-1 |
21/23 (91.3%) |
CA4;PCK2;FXYD2;...
|
| Glycolysis / Gluconeogenesis |
-1.37 |
3.30e-1 |
56/67 (83.58%) |
LDHA;HKDC1;ADH5;...
|
| Valine, leucine and isoleucine degradation |
-1.41 |
2.66e-1 |
42/48 (87.5%) |
BCKDHB;ALDH1B1;IVD;...
|
| Pyruvate metabolism |
-1.41 |
2.79e-1 |
41/47 (87.23%) |
PCK2;ME1;LDHB;...
|
| Peroxisome |
-1.41 |
2.93e-1 |
72/82 (87.8%) |
SCP2;PEX14;SLC25A17;...
|
| Riboflavin metabolism |
-1.42 |
3.04e-1 |
7/8 (87.5%) |
ACP5;BLVRB;ACP2;...
|
| Thyroid cancer |
-1.42 |
3.14e-1 |
36/37 (97.3%) |
TPM3;MYC;GADD45A;...
|
| Fat digestion and absorption |
-1.42 |
3.28e-1 |
35/43 (81.4%) |
PLA2G10;PLA2G5;CD36;...
|
| Neuroactive ligand-receptor interaction |
-1.43 |
3.36e-1 |
294/341 (86.22%) |
ADRA1D;SSTR4;TRH;...
|
| Mineral absorption |
-1.45 |
3.05e-1 |
48/60 (80%) |
ATP1A3;MT1H;MT2A;...
|
| Cardiac muscle contraction |
-1.48 |
2.69e-1 |
64/87 (73.56%) |
MYH6;CACNB4;CACNA2D2;...
|
| Glycerophospholipid metabolism |
-1.49 |
2.71e-1 |
71/98 (72.45%) |
PLA2G12A;PLA2G2D;ACHE;...
|
| Pancreatic secretion |
-1.49 |
2.95e-1 |
87/102 (85.29%) |
CELA3A;ATP2A3;ATP2B1;...
|
| Pantothenate and CoA biosynthesis |
-1.52 |
2.75e-1 |
14/21 (66.67%) |
ALDH1B1;DPYS;PANK3;...
|
| Hypertrophic cardiomyopathy |
-1.53 |
2.75e-1 |
81/90 (90%) |
TGFB3;CACNB1;PRKAG1;...
|
| Linoleic acid metabolism |
-1.54 |
2.92e-1 |
21/29 (72.41%) |
PLA2G10;PLA2G5;PLAAT3;...
|
| Cysteine and methionine metabolism |
-1.55 |
2.90e-1 |
43/50 (86%) |
PHGDH;LDHA;ENOPH1;...
|
| Selenocompound metabolism |
-1.57 |
3.13e-1 |
11/17 (64.71%) |
SEPHS1;TXNRD1;PAPSS1;...
|
| Arginine and proline metabolism |
-1.63 |
2.29e-1 |
39/50 (78%) |
ARG1;PRODH;ALDH1B1;...
|
| alpha-Linolenic acid metabolism |
-1.65 |
2.43e-1 |
17/25 (68%) |
FADS2;PLA2G10;PLA2G5;...
|
| Arachidonic acid metabolism |
-1.72 |
2.20e-1 |
48/61 (78.69%) |
ALOX15B;PLA2G10;LTA4H;...
|
| Ether lipid metabolism |
-1.96 |
5.62e-2 |
32/49 (65.31%) |
PLD3;GDPD3;PLA2G10;...
|
